Intervention not reported
Adverse events (vomiting) · children with acute diarrhoea
The intervention probably leads to higher adverse events (vomiting) (moderate certainty).
1 finding from 1 review
Adverse events Gross 2011 · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review
Adverse events: severe complications at day 21 · bullous pemphigoid
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Neurological adverse effects · acute soft tissue injury
NSAID probably leads to lower neurological adverse events compared with opioid (moderate certainty).
1 finding from 1 review
Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes neurological adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain
NSAID showed no clear difference in neurological adverse events compared with paracetamol (low certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection
1 finding from 1 review
Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection
It is very uncertain whether intramuscular ceftriaxone changes adverse events including treatment‐related adverse events compared with oral amoxicillin plus oral probenecid (very low certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · children with cystic fibrosis
1 finding from 1 review
Adverse events, OHSS, preterm delivery, congenital anomaly · women with gonadotropin plus oral (clomiphene citrate or letrozole) stimulation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, OHSS, preterm delivery, congenital anomaly · women with oral (clomiphene citrate or letrozole) stimulation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review